{
  "industry": "chemistry",
  "stage": "series-a",
  "pageType": "metrics-benchmarks",
  "slug": "/investor-questions/chemistry/series-a/metrics-benchmarks/",
  "ctaText": "Create your PitchChat room",
  "dataOrigin": "editorial",
  "sourceId": "editorial-chemistry-series-a",
  "sourceNotes": "Editorial guidance prepared by Pitchchat; not sourced from user submissions.",
  "sourceTags": [
    "editorial",
    "pitchchat-guidance"
  ],
  "title": "Chemistry Series A fundraising metrics benchmarks",
  "summary": "Series A biotech benchmarks focus on clinical readiness and data quality. Investors evaluate whether you've sufficiently de-risked to justify larger capital deployment. These benchmarks demonstrate transition from promising science to executable clinical program. Pitchchat keeps fundraising metrics investor-ready in one room.",
  "metrics": [
    {
      "label": "Development Stage",
      "value": "IND filed to Phase 2 ready",
      "note": "IND filed/cleared minimum. Phase 1 data significantly increases valuation and optionality.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Clinical Patients Treated",
      "value": "0-50 (Phase 1)",
      "note": "For clinical-stage: patients dosed in trials. Safety and early efficacy signals valuable.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "IND-Enabling Studies",
      "value": "Complete GLP tox package",
      "note": "GLP toxicology completed. CMC package IND-ready. Pharmacology studies supporting dose selection.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Regulatory Designations",
      "value": "1-2 obtained",
      "note": "Orphan drug, fast track, breakthrough therapy. Designations signal regulatory pathway clarity.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Patent Grants",
      "value": "2+ key markets",
      "note": "Composition-of-matter patents granted in US and EU minimum. Method claims supporting.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "CMO Under Contract",
      "value": "Clinical supply secured",
      "note": "Manufacturing partner contracted. Process locked for clinical material. Scale-up path identified.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Pharma Interest",
      "value": "Multiple parties engaged",
      "note": "CDAs with 3+ pharma companies. Active diligence or partnership discussions underway.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Scientific Advisors",
      "value": "5-10 active KOLs",
      "note": "Key opinion leaders actively engaged. Clinical trial site relationships. Publication support.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Team Size",
      "value": "15-40 people",
      "note": "Team scaled for clinical operations. CMO/CMC, regulatory, and clinical leads in place.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Non-Dilutive Funding",
      "value": "$2M - $10M cumulative",
      "note": "Grants, foundation support, collaborations. Demonstrates external validation and extends runway.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    }
  ]
}